Intratumoral therapy—in which cancer drugs are injected directly into tumors—is a promising treatment option for solid cancers but has shown limited success in clinical trials due to an inability to precisely deliver ...
Nov 13, 2023
0
42
A new research paper titled "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001" has been published in Oncotarget.
Jan 17, 2023
0
29
An increase in intracranial pressure (ICP) is a dangerous condition that can be caused by brain bleeds, a brain tumor, cerebral edema, traumatic brain injury, and hydrocephalus. ICP monitoring is thus a key aspect of patient ...
Oct 24, 2022
0
20
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis. Now, a preclinical study from the lab of Marsha Moses, Ph.D. at Boston ...
Nov 5, 2020
0
19
Hepatocellular carcinoma is a particularly stubborn form of cancer with few treatments and a high mortality rate. It is usually treated by blocking the flow of blood to the tumor to induce cancer cell death. The common treatment, ...
Sep 8, 2020
0
6
A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients.
Aug 15, 2019
0
32
In a study that will be published April 1 in the Journal of Experimental Medicine, researchers from the Institut Pasteur and INSERM reveal that chimeric antigen receptor (CAR) T cells can induce tumor regression by directly ...
Apr 1, 2019
0
42
Similar to humans, dogs live longer than before and an increasing number of them die from cancer. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and ...
Aug 25, 2017
0
82
A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.
Apr 18, 2016
0
2
Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical ...
Nov 9, 2015
0
3
